There have been suggestions that guided biopsies on the basis of multiparametric MRI (mpMRI) data are most accurate when done using so-called “in-bore” or “in-gantry” biopsies as opposed to mpMRI/TRUS fusion-guided biopsies. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, lesion, MRI, multiparametric, target | 6 Comments »
One of the key ways in which we can (and do) assess the “value” of new types of medical test is by the degree to which they actually change the ways physicians act on the data and make decisions and/or recommendations about patient management. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: active, biopsy, Diagnosis, risk, surveillance, Treatment | Leave a comment »
A newly published article in Reviews in Urology argues that, on economic grounds alone, the majority of patients thought to be at risk for prostate cancer should have a 4KScore test prior to them being given a biopsy since this test can rule out the need for biopsies with a high degree of accuracy. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, risk, test, work-up | 7 Comments »
Whatever one may happen to think about the value of the PSA test, we all know that it is very bad at actually telling a doctor or a patient if that patient is at real risk for clinically significant prostate cancer. So, from that perspective … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, evaluation, MRI, PSA, research, risk, work-up | 2 Comments »
A newly published study in the journal Urology (the “Gold Journal”) has suggested that — at least for patients with a PSA level between 4 and 10 ng/ml — PSA density may be better than PSA level in the determination of which of these patients need to go on to have a biopsy. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, density, Diagnosis, PSA, risk | 7 Comments »
A report on the HealthDay web site related to a presentation about the role of MRI scanning in the diagnosis of localized prostate cancer seems to demonstrate a significant division of views about the value of standardized use of mpMRI in the diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, MRI, PSA, risk, screening, testing | 1 Comment »
The role of baseline and repeat multiparametric MRI (mpMRI) scanning as a substitute for repeat biopsies in the initial evaluation and ongoing management of men on active surveillance continues to evolve. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: active, biopsy, monitoring, MRI, risk, serial, surveillance | 5 Comments »
